Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 9/20 | 0.51 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619333 | 0.94 | DRD2 (0.49) | SIGMAR1DRD2NPFFR1NPFFR2KMT2A | |
| SCHEMBL1618250 | 0.87 | DRD2 (0.45) | SIGMAR1DRD2ALDH1A1 | |
| SCHEMBL19734921 | 0.84 | SIGMAR1 (0.68) | SIGMAR1DRD2NPFFR1NPFFR2ALDH1A1 | |
| SCHEMBL4670377 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL18463376 | 0.83 | DRD2 (0.52) | SIGMAR1DRD2NPFFR1NPFFR2KMT2A | |
| SCHEMBL1619259 | 0.83 | CYP2D6 (0.42) | SIGMAR1DRD2NPFFR1NPFFR2KMT2A | |
| SCHEMBL30363139 | 0.83 | TDP1 (0.51) | SIGMAR1DRD2KMT2A | |
| SCHEMBL31165348 | 0.82 | NPFFR1 (0.49) | SIGMAR1DRD2NPFFR1NPFFR2ALDH1A1 | |
| SCHEMBL23924608 | 0.79 | SIGMAR1 (0.52) | SIGMAR1DRD2NPFFR1NPFFR2ALDH1A1 | |
| SCHEMBL23924607 | 0.79 | SIGMAR1 (0.52) | SIGMAR1DRD2NPFFR1NPFFR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ASTRAZENECA AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1915380-A1 | PROCESS FOR THE PREPARATION OF N,N´- DISUBSTITUTED OXABISPIDINES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006137770-A1 | PROCESS FOR THE PREPARATION OF N,N´- DISUBSTITUTED OXABISPIDINES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ADH1C, ADH5, ADH1A | SIGMAR1 116/4885DRD2 12/4885NPFFR1 174/4885 |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | SIGMAR1 975/4885DRD2 553/4885NPFFR1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.